PharmExec
JULY 10, 2023
Join five industry leaders as they unpack the transformative potential of artificial intelligence in the pharmaceutical industry, offering insights into real-world applications and the future of life sciences marketing in an era shaped by rapid technological evolution.
Fierce Pharma
JULY 11, 2023
Caught in a litigation crossfire, Moderna has reportedly opened two new fronts in its COVID-19 vaccine patent war with Pfizer and BioNTech. | Moderna has lodged two new lawsuits at the High Court in Dublin, Ireland, and the Brussels Commercial Court in Belgium, Juve Patent first reported. This adds to a complex web of ongoing mRNA patent litigation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
JULY 11, 2023
There are three key areas of the healthcare sector where generative AI is booming the most — in terms of both venture capital funding and the development of innovative technology — according to Anjalika Komatireddy, an analyst at CB Insights. During a recent webinar, she discussed the generative AI activity occurring in these three areas: care delivery and navigation, digital therapeutics and drug discovery.
Pharmaceutical Commerce
JULY 11, 2023
The National Alliance of Healthcare Purchaser Coalitions releases resources for employers/health plan purchasers to offer insights on PBMs role in high prescription drug costs.
PM360
JULY 13, 2023
PM360 asked six CEOs at companies developing cancer treatments to provide an update on the latest and most exciting breakthroughs in their respective areas of expertise including: antibody-drug conjugates, CAR-T immunotherapies, cytokine-based therapy, mRNA/epigenetics, precision immuno-oncology, and small molecules. Dan O’Connor Most Exciting Development Within Your Area of Cancer Treatments The most exciting development within the antibody-drug conjugate (ADC) space is site-specific conjugatio
Fierce Pharma
JULY 10, 2023
Two cases of suicidal thoughts and one case of self-harm from users in Iceland of Novo Nordisk’s diabetes and obesity drugs have prompted the European Medicines Agency (EMA) to review the blockbust | Two cases of suicidal thoughts and one case of self-harm from users in Iceland of Novo Nordisk’s diabetes and obesity drugs have prompted the European Medicines Agency (EMA) to review the blockbuster products.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Copyright Clearance Center
JULY 13, 2023
After introducing The State of Scholarly Metadata: 2023 interactive report this April at the London Book Fair, we have continued to facilitate conversations about the importance of quality metadata with those in scholarly communications.
PM360
JULY 13, 2023
“Drugs don’t work in patients who don’t take them,” C. Everett Koop, MD, U.S. Surgeon General, said in 1985. Novartis’ analysis of claims data from Nov. 2020 to Oct. 2021 revealed that roughly one in four prescriptions were never filled. 1 In addition, of patients who began therapy, more than 70% were no longer on their prescribed medication after 12 months. 1 Patients may discontinue if they cannot afford their out-of-pocket costs even with insurance coverage due to side effects or lack of perc
Fierce Pharma
JULY 10, 2023
Just days after sewing up a pair of $897 million deals with Pfizer, Samsung Biologics has added a few hundred million dollars more to its partnership cash pile—this time courtesy of an expanded pac | Samsung Biologics said in a Monday regulatory filing that it’s inked a $390.9 million deal to help crank out Novartis drugs. The latest production pact builds on an earlier tie-up worth $81 million.
Pharma Marketing Network
JULY 13, 2023
When it comes to marketing your pharma business on Facebook, you may be wondering whether you should boost a post or create an ad. Both have their own advantages and disadvantages, so it’s important to choose the right option for your needs. Boosting a post is a quick and easy way to get more exposure for your content. When you boost a post, you’re essentially paying to increase its reach and visibility.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmExec
JULY 12, 2023
Recent data and commentary offer insights into how biologics vs. small molecule patent protections under the Inflation Reduction Act pricing scenarios is impacting investing in the biotech sector.
PM360
JULY 13, 2023
A 2019 study published in the Journal of Medical Internet Research mHealth and uHealth found 704 apps related to medication adherence available from Apple (443) and Android (261). And that was four years ago! I imagine anyone willing to count the apps available today would find even more. And yet, the issue of medication nonadherence persists to this day—but it is clearly not for a lack of trying.
Fierce Pharma
JULY 12, 2023
As another SGLT2 diabetes drug hits the market, the obvious question is: How will it find a way to compete against formidable blockbusters Farxiga and Jardiance? | TheracosBio and Mark Cuban's online distributor Cost Plus Drug Company have partnered to provide newly approved SGLT2 inhibitor Brenzavvy at a major discount to competitors in the class, including AstraZeneca's Farxiga and Eli Lilly and Boehringer Ingelheim's Jardiance.
Pharma Marketing Network
JULY 12, 2023
The internet is a vast resource of information on health and wellness. However, not all of this information is created equal. Some of it is accurate and reliable, while other information may be misleading or even harmful. This is especially true when it comes to pharmaceutical-sponsored health information. Pharmaceutical companies have a vested interest in promoting their products, so it’s important to be critical of any information they put out.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
PharmExec
JULY 10, 2023
Artificial intelligence is steadily becoming a game changer for the pharma industry, particularly in commercialization activities, such as sales and marketing—and efforts to help highly sought treatments reach the right patients.
PM360
JULY 13, 2023
During the COVID-19 pandemic, we saw healthcare organizations spend and scramble to implement numerous virtual care point solutions. The global healthcare IT market was valued at $280.3 billion in 2020 and is expected to reach $381.7 billion by 2025, growing at a compound annual growth rate of 6.7%. 1 This increased technology spending has led to industry fragmentation, creating siloed data—which can leave providers with an incomplete picture of a patient’s health record—and an often-cumbersome
Fierce Pharma
JULY 13, 2023
With the multiple sclerosis market growing rapidly—from $18.9 billion in 2020 to a projec | A phase 3 study has shown that a new, subcutaneous version of Roche's Ocrevus has proven to be non-inferior to the current infused treatment as measured by the level of drug in the blood, 12 weeks after administration. An approval for the injected version would allow patients to receive treatment in 10 minutes as opposed to four hours, every six months.
Pharma Marketing Network
JULY 13, 2023
The pharmaceutical industry is a highly regulated industry, and as such, marketing strategies must be carefully planned and executed. However, this does not mean that out-of-the-box marketing is not possible or effective. In fact, in some cases, out-of-the-box marketing can be the most effective way to reach target audiences and achieve marketing goals.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
PharmExec
JULY 10, 2023
COMPASS Pathways’ CEO, Kabir Nath, has a clear vision for psychedelics—and is leading the way with the company’s focus on psilocybin and efforts to separate the science from the hype.
PM360
JULY 13, 2023
PM360 asked experts in helping patients stay on their prescribed therapies about where the industry could make the biggest improvements and how to better detect potential barriers. Specifically, we asked them: What is the biggest area where the industry could stand to improve its approach to boosting adherence? Why is the industry currently doing poorly in this area?
Fierce Pharma
JULY 12, 2023
Merck is bringing more heat in its battle against drug price negotiation provisions in the Inflation Reduction Act (IRA), filing Tuesday in federal court in Washington, D.C. | Merck is bringing more heat in its battle against drug price negotiation provisions in the Inflation Reduction Act (IRA), filing Tuesday for a decision without a trial. In its request for a summary judgment, Merck reiterated its claim that the drug price negotiation program violates the First and Fifth Amendments of the Co
Pharma Marketing Network
JULY 12, 2023
The pharmaceutical industry is facing a number of challenges, including increasing competition, rising costs, and changing regulations. In order to succeed in this challenging environment, pharmaceutical companies need to adopt a patient-centric approach to marketing. Patient-centric pharmaceutical marketing is based on the understanding that patients are more than just consumers of drugs.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
JULY 11, 2023
HCA Healthcare recently suffered a data breach affecting 1,038 hospitals and physician clinics across 20 states. The health system said hackers stole data from an external data storage location “exclusively used to automate the formatting of email messages.” It also said that the incident has not caused any disruption to HCA’s daily operations or the services it provides to patients.
PM360
JULY 13, 2023
The media planning landscape in the pharmaceutical industry has significantly changed over the last few decades, especially since the pandemic. Pharmaceutical companies are faced with the ongoing challenge of maximizing efficiency and ROI while maintaining a strong focus on quality research and development. Although marketers have many options to manage their media planning and buying, the right model and mix are key for the ongoing success of brand marketing.
Fierce Pharma
JULY 14, 2023
As Johnson & Johnson awaits a decision on its second attempt to resolve talc lawsuits through a bankruptcy ploy, the company is attempting another legal tactic to free itself from those liabili | As Johnson & Johnson awaits a decision on its second attempt to resolve talc lawsuits through a bankruptcy ploy, the company is attempting another legal tactic to help free itself from those liabilities—suing doctors who say that its iconic baby powder can cause cancer.
Pharma Marketing Network
JULY 13, 2023
Your website is your online storefront, so it’s important to choose the best web development company to create it. In the pharmaceutical industry, where trust and credibility are essential, it’s especially important to choose a web development company that understands the specific needs of your business. Here are some factors to consider when choosing a web development company for the pharmaceutical industry: ● Experience in the pharmaceutical industry: Make sure the company you choo
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
European Pharmaceutical Review
JULY 10, 2023
As of 7 July 2023, the European Medicines Agency (EMA) has updated its guidance on nitrosamine impurities. The regulatory body has amended Q&A 10 to include the Carcinogenic Potency Categorization Approach (CPCA) and the enhanced Ames test (EAT) for establishing acceptable intakes (AIs) for N -nitrosamines. The assessment report of the Committee for Medicinal Products for Human Use (CHMP)’s Article 5(3) of Regulation (EC) No 726/2004 opinion on nitrosamine impurities in human medicinal produ
PM360
JULY 13, 2023
“People adhere to medicines at a scale that should bewilder everyone in healthcare,” exclaims Grace Lomax, Clinical Director of Patient Connect , part of Clarivate. If you work in this industry and are not yet bewildered by the issue of medication nonadherence, allow Grace Lomax to put things into perspective. “Only 8% of people taking ramipril—one of the most highly prescribed cardiovascular drugs in the world—are fully adherent over 12 months.
Fierce Pharma
JULY 13, 2023
After a full FDA approval last week triggered Medicare coverage of Eisai and Biogen’s Leqembi, doctors are still trying to work out the logistics of testing and reimbursement. | After a full FDA approval last week triggered Medicare coverage of Eisai and Biogen’s Leqembi, doctors are still working out the logistics of testing and reimbursement. But at least two experts remain positive about the drug’s efficacy and safety profile.
MedCity News
JULY 14, 2023
Inflammation and immunology biotech Apogee Therapeutics and Sagimet Biosciences, a company developing a drug for the fatty liver disease NASH, are the latest biotech companies to join the public markets. Both companies upsized their IPOs, raising cash for clinical trials.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Expert insights. Personalized for you.
119 
Let's personalize your content